A Phase 1 interventional study of Nintedanib and Nintedanib in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-27.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the current study is to investigate the relative bioavailability of a single dose of nintedanib low or high dose with and without coadministration of ketoconazole at steady state
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
single dose, oral with 240 ml water
Drug: Nintedanib
Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
Drug: Ketoconazole · Drug: Nintedanib
single dose, oral with 240 ml water
Drug: Nintedanib
Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
Drug: Nintedanib · Drug: Ketoconazole
low or medium dose depending on pilot part
low dose oral administration
oral administration
low dose oral administration
low or medium dose depending on pilot part
oral administration
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)
AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
Time frame: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration
Maximum Measured Concentration (Cmax)
Cmax represents the maximum concentration of nintedanib in plasma For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
Time frame: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration
Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)
AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from time 0 to the last quantifiable nintedanib plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
Time frame: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration
| Milestone | Nintedanib (Pilot Part)/ Nintedanib+Ketoconazole (Pilot Part) | Nintedanib+Ketoconazole (Pilot Part)/ Nintedanib (Pilot Part) | Nintedanib (Main Part)/ Nintedanib+Ketoconazole (Main Part) | Nintedanib+Ketoconazole (Main Part)/ Nintedanib (Main Part) |
|---|---|---|---|---|
| Started | 4 | 4 | 13 | 13 |
| Received nintedanib (pilot) | 4 | 3 | 0 | 0 |
| Received nintedanib+ketoconazole (pilot) | 4 | 4 | 0 | 0 |
| Received nintedanib (main) | 0 | 0 | 13 | 11 |
| Received nintedanib+ketoconazole (main) | 0 | 0 | 13 | 13 |
| Completed | 4 | 3 | 11 | 11 |
| Not completed | 0 | 1 | 2 | 2 |
| Withdrew: Other than stated above | 0 | 1 | 2 | 2 |
AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
| ng*h/mL | Nintedanib | Nintedanib + Ketoconazole |
|---|---|---|
| Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞) | 38.6 ± 42.5 | 61.3 ± 40.4 |
Cmax represents the maximum concentration of nintedanib in plasma For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
| ng/mL | Nintedanib | Nintedanib + Ketoconazole |
|---|---|---|
| Maximum Measured Concentration (Cmax) | 4.19 ± 71.0 | 7.13 ± 44.4 |
AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from time 0 to the last quantifiable nintedanib plasma concentration. For this endpoint, the "measured values" show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
| ng*h/mL | Nintedanib | Nintedanib + Ketoconazole |
|---|---|---|
| Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz) | 35.7 ± 47.8 | 59.4 ± 40.8 |
Collected over From the first trial drug administration until 18 days after the last trial drug administration, up to 32 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ketoconazole | — | 0/34 (0%) | 2/34 (5.9%) |
| Nintedanib | — | 0/31 (0%) | 6/31 (19.4%) |
| Nintedanib + Ketoconazole | — | 0/29 (0%) | 6/29 (20.7%) |
| Event | Ketoconazole | Nintedanib | Nintedanib + Ketoconazole |
|---|---|---|---|
| HeadacheNervous system disorders | 2/34 | 5/31 | 5/29 |
| Back painMusculoskeletal and connective tissue disorders | 0/34 | 0/31 | 2/29 |
| NasopharyngitisInfections and infestations | 0/34 | 2/31 | 1/29 |
The treated set (TS) includes all subjects who were dispensed study medication and were documented to have taken at least one dose of study medication (nintedanib or ketoconazole).
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 35.9 ± 10.7 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 0 |
| Male | 34 |
The record gives a start of Sep 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib